Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Different subsets of CesA isoforms are necessary for primary and secondary cell wall biogenesis. Here, we structurally and functionally characterize the Glycine max (soybean) primary cell wall CesAs ...

During cellulose synthesis in the primary cell wall this is composed of members of groups CESA1, CESA3 and CESA6. While the authors have previously presented structural data on CESA8, required for ...

The cells were then incubated with FITC-conjugated secondary antibodies ... was lower than some other cell lines, such as Caco-2 with a well-developed brush border (32). Microvilli with a low density ...

IFx-Hu2.0 is designed to overcome primary resistance to checkpoint ... compared to Keytruda® plus placebo in first line treatment for advanced or metastatic Merkel Cell Carcinoma.

IFx-Hu2.0 is designed to overcome primary resistance to checkpoint inhibitors ... trials in melanoma and advanced or metastatic Merkel cell carcinoma (MCC). "Like our planned Phase 3 accelerated ...

To copy itself, however, LINE-1 must enter each cell's nucleus, the inner barrier that houses DNA. Now a new study, published online in the journal Science Advances, reveals that LINE-1 binds to ...

Copyright: © 2019 Elsevier Ltd. All rights reserved.